COLLEGIUM PHARMACEUTICAL, INC (COLL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 300M 600M 900M FY16: 1.7M FY17: 28.5M FY18: 280.4M FY19: 296.7M FY20: 310M FY21: 276.9M FY22: 463.9M FY23: 566.8M FY24: 631.4M FY25: 780.6M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 200M 400M 600M FY18: 114.7M FY19: 103M FY20: 179.8M FY21: 150.6M FY22: 209.5M FY23: 326.2M FY24: 377.3M FY25: 463.3M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-140M -70M 0 70M 140M 210M FY13: -16M FY14: -17.7M FY15: -26.9M FY16: -94.1M FY17: -75.4M FY18: -20.7M FY19: -23.7M FY20: 56.2M FY21: 17.6M FY22: 33.3M FY23: 167M FY24: 169.9M FY25: 179.6M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-105M -70M -35M 0 35M 70M 105M FY13: -16.2M FY14: -17.9M FY15: -27.3M FY16: -94.2M FY17: -74.9M FY18: -39.1M FY19: -22.7M FY20: 26.8M FY21: 71.5M FY22: -25M FY23: 48.2M FY24: 69.2M FY25: 62.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150M 300M 450M FY16: 213K FY17: 2.6M FY18: 165.7M FY19: 193.7M FY20: 130.2M FY21: 126.3M FY22: 254.4M FY23: 240.6M FY24: 254.1M FY25: 317.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-150M 0 150M 300M 450M FY13: -16.5M FY14: -17.9M FY15: -21.6M FY16: -75.1M FY17: -67M FY18: 169.4M FY19: 27.8M FY20: 93.9M FY21: 103.6M FY22: 124.2M FY23: 274.7M FY24: 205M FY25: 329.3M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-150M 0 150M 300M 450M FY13: -16.7M FY14: -18M FY15: -21.9M FY16: -75.5M FY17: -68M FY18: 163.9M FY19: 21.3M FY20: 88.4M FY21: 101.6M FY22: 122.6M FY23: 274.3M FY24: 203.3M FY25: 327.6M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY18: 33M FY19: 33.5M FY20: 35.2M FY21: 41M FY22: 33.8M FY23: 41.8M FY24: 40.4M FY25: 39.7M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '14: -22.71 Q1 '15: -18.33 Q2 '15: -13.45 Q3 '15: -6.06 Q4 '15: -2.02 Q1 '16: -2.05 Q2 '16: -2.65 Q3 '16: -3.32 Q4 '16: -3.88 Q1 '17: -3.99 Q2 '17: -3.66 Q3 '17: -2.98 Q4 '17: -2.50 Q1 '18: -2.28 Q2 '18: -1.96 Q3 '18: -2.01 Q4 '18: -1.20 Q1 '19: -0.92 Q2 '19: -0.66 Q3 '19: -0.34 Q4 '19: -0.67 Q1 '20: -0.37 Q2 '20: -0.00 Q3 '20: 0.50 Q4 '20: 0.76 Q1 '21: 1.16 Q2 '21: 2.72 Q3 '21: 2.62 Q4 '21: 1.69 Q1 '22: 0.89 Q2 '22: -1.05 Q3 '22: -1.26 Q4 '22: -0.74 Q1 '23: -0.86 Q2 '23: -0.37 Q3 '23: 0.15 Q4 '23: 1.18 Q1 '24: 2.40 Q2 '24: 2.58 Q3 '24: 2.32 Q4 '24: 1.86 Q1 '25: 1.22 Q2 '25: 1.04 Q3 '25: 1.61 Q4 '25: 1.71 Q1 '26: 2.04 Q2 '26: 1.24 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.